Participants in the study will receive either Ustekinumab or Guselkumab over a period of up to 52 weeks. The study will monitor the participants’ response to the treatment, including any changes in their arthritis symptoms and any side effects they may experience. The study will also look at how the body absorbs and breaks down the medications, which is known as pharmacokinetics. This information will help determine the best dosage and frequency for these medications in treating Juvenile Psoriatic Arthritis.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on the use of Ustekinumab and Guselkumab in young patients with Juvenile Psoriatic Arthritis, potentially leading to better treatment options for managing this condition. The study will also gather data on the immune response to these medications, which is important for understanding their long-term safety and effectiveness.

The purpose of the study is to evaluate how well risankizumab works, how safe it is, and how it is processed by the body in children aged 5 to under 18 years who have active juvenile psoriatic arthritis. These children may not have responded well to other treatments like methotrexate or similar medications. Participants in the study will receive either risankizumab or adalimumab, and their progress will be monitored over a period of time to see how their symptoms change.

The study will last for about 124 weeks, during which time participants will have regular check-ups to assess their response to the treatment. The main goal is to see if the children achieve a significant improvement in their arthritis symptoms by the 24th week of the study. Additional assessments will be made to measure changes in pain levels, skin symptoms, and overall disease activity. This information will help determine the effectiveness and safety of risankizumab for treating juvenile psoriatic arthritis in children.

The treatment being studied is Guselkumab, a type of medication known as a monoclonal antibody. This medication is given as an injection under the skin using a pre-filled syringe. The study aims to observe how safe this medication is when used over a long period in young patients with these conditions. Participants in the study will receive the medication and be monitored by healthcare professionals to ensure their safety and to gather information about any side effects they might experience.

The study will take place over a period of time, allowing researchers to collect data on the long-term effects of Guselkumab. Participants will continue to receive the medication as part of their treatment plan, and their health will be regularly checked by the study team. This research is important to understand how well the medication works and how safe it is for children and teenagers with these specific health conditions.

The purpose of the study is to evaluate how effective Ixekizumab is in treating these types of arthritis in children. The study will involve giving the medications through a subcutaneous injection, which means the medicine is injected under the skin. Children participating in the study will receive either Ixekizumab or Adalimumab, and their progress will be monitored over time to see how well the treatments work in reducing symptoms of arthritis.

Throughout the study, researchers will observe the safety and tolerability of the treatments, ensuring that they are safe for use in children. The study aims to provide valuable information on how these medications can help manage juvenile idiopathic arthritis, potentially improving the quality of life for children affected by these conditions.

The purpose of this study is to gather information on the long-term safety of ustekinumab in young patients who have already participated in a previous study with this medication. Participants will continue to receive the medication over a period of time, and their health will be monitored to ensure the treatment remains safe. The study will involve regular check-ups and assessments to track any side effects or changes in the participants’ conditions.

Throughout the study, researchers will pay close attention to any adverse events, which are unexpected medical problems that may occur during treatment. They will also monitor for any reactions at the injection site and any changes in the participants’ health that might indicate a worsening of their disease. The study aims to provide valuable information about the long-term use of ustekinumab in managing these chronic conditions in young patients.

The purpose of this study is to learn if bimekizumab is safe and how it moves throughout the body in children with these types of arthritis. The study will involve children aged 2 to less than 18 years who have active disease. Participants will receive bimekizumab injections and will be monitored over a period of time to see how the medication affects them. The study will also look at any side effects that may occur and how the children’s health changes during the study.

Throughout the study, researchers will measure the levels of bimekizumab in the blood and observe any changes in the participants’ health, including their growth and vital signs like blood pressure and heart rate. The study will also assess any reactions at the injection site and monitor for any serious side effects, such as infections or other health issues. This information will help determine the safety and effectiveness of bimekizumab for treating these types of juvenile arthritis in children.